Voltar
Revisão Revisado por pares
BIBTEX RIS

Trastuzumab — Mechanism of Action and Use in Clinical Practice

2007; Massachusetts Medical Society; Volume: 357; Issue: 1 Linguagem: Inglês

10.1056/nejmra043186

ISSN

1533-4406

Autores

Clifford A. Hudis,

Tópico(s)

Peptidase Inhibition and Analysis

Resumo

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent.

Referência(s)